Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 years of age or older~* History of migraine with or without aura for more than 1 year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to starting in the study~* Willing to stay awake for at least 2 hours after taking study drug~* Able to read, understand and complete questionnaires and diaries~Exclusion Criteria:~* Breast-feeding, pregnant, or plan to become pregnant during the study~* Not able to tell migraine attack from other headaches~* Older than 50 years of age at migraine onset~* Have more than 15 headache days per month or have taken medication for acute headache on more than 10 days per month in any of the 3 months before starting in the study~* History of gastric or small intestinal surgery~* History of heart attack, stroke, unstable angina, coronary artery bypass surgery or transient ischemic attack in the 3 months before starting in the study~* Currently participating or have participated in a study with in investigational compound or device in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
- Telcagepant 280 mg +Ibuprofen 400 mg (Type: EXPERIMENTAL): Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
- Telcagepant 280 mg +APAP 1000 mg (Type: EXPERIMENTAL): Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
- Telcagepant 280 mg (Type: PLACEBO_COMPARATOR): Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine

Based on this trial design, predict the completion outcome and termination type (if applicable).